SS-31 (Elamipretide) Is the First Longevity Peptide the FDA Approved

On September 19, 2025, the FDA granted accelerated approval to Forzinity (elamipretide injection) for improving muscle strength in patients with Barth syndrome weighing at least 30 kg. That sentence sounds narrow. It is not.

Elamipretide, originally known as SS-31 in the research literature, is the first FDA-approved drug that directly targets mitochondrial dysfunction. For a field that has spent decades producing pre-clinical excitement with zero clinical translations, this is a watershed moment.

What Elamipretide Actually Does

SS-31 is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that crosses membranes and selectively binds cardiolipin on the inner mitochondrial membrane. Cardiolipin is the lipid scaffold that organizes electron transport chain supercomplexes. When cardiolipin is damaged or depleted (as happens in aging, metabolic disease, and Barth syndrome), electron transport becomes inefficient, reactive oxygen species spike, and ATP production drops.

By stabilizing cardiolipin, elamipretide:

• Restores respiratory chain supercomplex assembly
• Enhances electron transport efficiency and ATP production
• Reduces mitochondrial ROS generation at the source
• Dampens downstream inflammatory signaling from mitochondrial distress

This is not a temporary energy boost. It is structural repair of the organelle that produces 90% of cellular energy.

The Barth Syndrome Story

Barth syndrome is a rare, life-threatening X-linked mitochondrial disorder caused by mutations in the TAFAZZIN gene, which encodes an enzyme essential for cardiolipin remodeling. It primarily affects males and has an estimated prevalence of ~1 in 400,000-500,000 live births (~150 patients in the U.S.).

The clinical trial was a randomized, double-blind, placebo-controlled crossover study. The primary six-minute walk test didn’t reach significance initially, but a 168-week open-label extension showed sustained improvements in knee extensor strength. The FDA ultimately accepted knee extensor strength as an intermediate endpoint for accelerated approval, recognizing its correlation with functional outcomes.

The road to approval was grueling: an initial rejection, an advisory committee vote of 10-6 in favor, manufacturing facility inspections, and a resubmission before final approval in September 2025.

Why This Matters Beyond Barth Syndrome

Barth syndrome is the entry point, not the destination. Elamipretide has been investigated or is being studied in:

• Primary Mitochondrial Myopathy (NuPower trial) -- Phase 3 results pending; could impact thousands of mitochondrial disease patients
• Heart failure with preserved ejection fraction (HFpEF) -- Mitochondrial dysfunction is increasingly recognized as a driver of diastolic dysfunction
• Age-related muscle decline -- In aged mice, SS-31 significantly improved exercise tolerance, muscle strength, and mitochondrial efficiency (Siegel et al., Aging Cell, 2013)
• Renal ischemia and diabetic nephropathy -- Reduced ROS and improved renal function in animal models
• Cardiac ischemia-reperfusion injury -- Protection of mitochondrial structure after ischemic stress

Every aging cell has declining mitochondria. A drug that demonstrably repairs mitochondrial function in one disease creates the proof-of-concept for dozens of others. That’s why longevity researchers consider elamipretide’s approval a category-level inflection point, not just a rare-disease story.

The Research Peptide Angle

SS-31 has been available through research peptide vendors for years. The FDA approval of the commercial formulation (Forzinity) validates the mechanism but doesn’t directly change research-grade availability. For researchers interested in mitochondrial peptides, SS-31 remains available for in-vitro and pre-clinical investigation.

Frequently Asked Questions

Related Articles